What is known and objective: Flibanserin is a serotonin 5-HT 1A agonist and 5-HT 2A antagonist approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Because of the increased risk of hypotension-and syncope-related adverse events (AEs) observed with coadministration of flibanserin and alcohol, alcohol use is contraindicated. To provide a more comprehensive understanding of the interaction between flibanserin and alcohol, the results of a dedicated phase 1 alcohol-interaction study and a pooled analysis of phase 3 studies of premenopausal women with HSDD are presented.
| WHAT IS KNOWN AND OBJECTIVE
Hypoactive sexual desire disorder (HSDD) is a common sexual dysfunction disorder, affecting up to 10% of women in the United States, [1] [2] [3] with similar prevalence worldwide. [4] [5] [6] HSDD is characterized by low sexual desire and associated distress. [7] [8] [9] Although antagonist. 13, 14 The function of flibanserin at these post-synaptic receptors is hypothesized to increase dopamine and norepinephrine in the prefrontal cortex and decrease serotonin 15, 16 ; all three neuromodulators are thought to play key roles in the regulation of sexual arousal and desire. 17 Although most research regarding neurobiological control of the mammalian sexual response has been conducted in animal models, adequate sexual functioning in humans may result from the proper balance of excitatory and inhibitory signals. 17 Dopamine and norepinephrine, with melanocortins, oxytocin and steroid hormones (ie, testosterone and oestrogen), are thought to be important for the excitatory response, whereas serotonin, with endocannabinoids and opioids, may be involved in regulating the inhibitory response. 17 The pathophysiology of HSDD is hypothesized to result from a hypoactive excitatory response, a hyperactive inhibitory response, or both 17, 18 ; the effects of flibanserin may counteract this imbalance, resulting in the restoration of sexual desire. 19 The safety and efficacy of flibanserin were examined across multiple phase 1, 2 and 3 studies in pre-and post-menopausal women with HSDD (and safety in healthy men); more than 1500 premenopausal women with HSDD received the recommended dose of flibanserin 100 mg daily at bedtime for ≥6 months. 20 The most commonly reported adverse events (AEs) were dizziness, somnolence, nausea, fatigue and insomnia, consistent with the classification of flibanserin as a central nervous system (CNS) depressant; 5-HT 1A agonism promotes wakefulness and inhibits sleep, 21 whereas 5-HT 2A antagonism causes sedation. 22 The risk of CNS depression and hypotension-and syncope-related AEs is increased when flibanserin is combined with alcohol; therefore, concomitant use of alcohol is contraindicated. To better define the interaction between flibanserin and alcohol, the results of a phase 1 alcohol-interaction study examining the safety and pharmacodynamic effects of concomitant flibanserin and alcohol use, and the effects of alcohol use in a phase 3 target population, are described. 
| METHODS

| Assessments
The primary end points for this study were change from baseline in 
| Statistical analyses
The safety population was defined as all participants who received ≥1
dose of study drug. The pharmacokinetic population was defined as all randomized participants completing the study for which there were a sufficient number of quantifiable plasma samples for reliable estimation of AUC 0-4 . Summary statistics are presented, unless otherwise specified. The analysis included patients who received flibanserin 100 mg daily at bedtime, or placebo; other flibanserin-dose groups were excluded.
| Phase 3 placebo-controlled flibanserin studies in premenopausal women with HSDD
Self-reported alcohol use was determined at baseline; participants were instructed to continue their usual habits. For studies 70, 71, 75
and 77, alcohol use was reported as "does not drink alcohol," "drinks alcohol but should not interfere with participation in the trial," or "drinks alcohol and could interfere with participation in the trial." For Study 147, alcohol use was reported as 0 drinks/day, 1-3 drinks/day or ≥3 drinks/day. AE data were analysed by baseline alcohol use. 
| Phase 1 study
A total of 25 participants were randomly assigned to one of five treatment sequence groups (five participants per sequence; Figure 1 ), of which 92% (23/25) completed all study activities. The study population consisted of 23 males and two females (Table 1) , who had a mean age of 30 years and most (76%) were white. The majority of participants were male due to difficulty in recruiting female participants who were moderate drinkers (~5 to 21 units of alcohol/week).
| Pharmacokinetic evaluations
The pharmacokinetic analysis included flibanserin data for 23 partici- Table 2 . Mean exposure of flibanserin through 4 hours (AUC 0-4 ) was similar among the treatment groups, indicating alcohol does not significantly affect flibanserin metabolism within 4 hours. sitting systolic blood pressure, diastolic blood pressure or pulse rate for up to 24 hours after dosing.
| Pharmacodynamic evaluations
Orthostatic vital signs
The incidence of hypotension and syncope was increased when flibanserin was coadministered with ethanol 0.4 g/kg or 0.8 g/kg (Table 3) . Table 3) .
Oxygen saturation
Oxygen saturation was unchanged from baseline in all treatment groups (data not shown).
T A B L E 1 Phase 1 dedicated alcohol-interaction study: demo graphic and baseline characteristics 
| Sedation visual analogue scale
Based on VAS score, sedation increased from 1.5 to 2.0 hours postdose with all treatments (Table 5 ). Sedation increased 20% and 27% from baseline with flibanserin plus 0.4 g/kg ethanol and flibanserin plus 0.8 g/kg ethanol, respectively, at 4 hours.
| Phase 3 studies
| Randomized, double-blind, placebo-controlled, 24-week trials in premenopausal women
Of the participants randomly selected to receive flibanserin 100 mg once daily at bedtime (n=1543), or placebo (n=1905), 58.2% and 63.6%, respectively, reported some level of alcohol use at baseline (Table 6) 
| DISCUSSION
Flibanserin is the first pharmacologic agent approved for the treat- T A B L E 4 Phase 1 dedicated alcohol-interaction study: incidence of treatment-emergent adverse events occurring in ≥3 participants AEs compared with flibanserin administered alone, there are several limitations to the dedicated alcohol-interaction study, in addition to the clinically unrealistic approach to dosing as described above.
Participants experienced acute exposure to flibanserin in this study, in contrast with chronic exposure in a real-world setting. Therefore, if tolerance occurs with chronic administration, the acute exposure of this study population may overestimate the effect. In addition, this preliminary study was small (N=25) and comprised predominantly of men, which is not the indicated patient population for flibanserin. As peak blood alcohol levels are typically higher in women compared with men after consuming equivalent doses of alcohol (even with adjustment for body weight), 24 Additionally, acute alcohol consumption increased heart rate and decreased baroreceptor reflex sensitivity in normotensive individuals. 26 Characterization of pharmacokinetics over a longer (eg, 24-hour) sampling period in additional studies of flibanserin and alcohol is warranted.
The hypotensive effects observed with flibanserin and alcohol may be due to depression of α-adrenoceptor-mediated vasoconstriction, which may result in impaired blood pressure control. 27 Orthostatic hypotension has also been reported after coadministration of alcohol with several tricyclic antidepressants 28 -amitriptyline, clomipramine, desipramine and imipramine-all of which show some degree of α1-adrenergic receptor antagonism. 29 However, this is merely hypothetical, and the mechanistic underpinnings of the pharmacodynamic interaction between alcohol and flibanserin remain to be elucidated; given the complex pharmacology of both agents, the increase in hypotensive events seen upon coadministration most likely involves activity at more than one neuromodu- 
| WHAT IS NEW AND CONCLUSIONS
The regulatory approval of flibanserin in premenopausal women with acquired, generalized HSDD marks a significant advancement in the treatment of female sexual dysfunction disorders. As with any prescription drug, the benefits of flibanserin must be weighed against the risks to inform a decision regarding the appropriate treatment options for each patient. Data regarding the interaction of flibanserin and alcohol presented herein are intended to aid in formulating an informed decision. More than half of premenopausal women (58%) included in the phase 3 studies reported concurrent alcohol consumption, but a meaningful risk of clinically significant hypotension was not observed.
Preliminary data from a dedicated phase 1 alcohol-interaction study suggested that the observed additive effects of concomitant alcohol and flibanserin consumption are pharmacodynamic rather than pharmacokinetic in nature. Limitations noted for both the dedicated alcohol-interaction study (eg, morning dosing, predominantly male participants) and the randomized, placebo-controlled studies (eg, no monitoring of alcohol use) minimize the clinical relevance of the results. Nonetheless, the pharmacodynamic interaction of flibanserin and alcohol observed in the phase 1 study is a significant concern.
Additional studies are currently being conducted to address previous limitations (eg, study population of premenopausal women, inclusion of a single drink-equivalent condition) and further elucidate the interactive, pharmacodynamic effects of flibanserin and alcohol on sedation-, hypotension-and syncope-related events. 
